Pharmafile Logo

Inizio launches Intelligent Congress: Turning medical event investment into measurable impact

May 12, 2026 |  

Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize the value of congress investment and deliver measurable business impact.

- PMLiVE

Medical congresses remain one of the most critical data milestones in an asset’s development, providing valuable opportunities to translate scientific innovation into clinical practice. However, many organizations still approach congresses as standalone events, with fragmented planning across therapy area teams, limited alignment to overarching disease area objectives, and limited clarity on measuring success beyond immediate metrics. 

By operating as a single, integrated partner across the full data and congress lifecycle, Inizio helps clients navigate complexity, align stakeholders, and gain clearer confidence in the impact of their congress investments. Our strength lies in an unmatched vantage point – combining deep, cross-functional expertise with end-to-end visibility across the product lifecycle. 

Intelligent Congress is built on this foundation. Drawing on more than 30 years of experience across therapy areas, it unites strategy, experience design, delivery, and measurement into one cohesive model. This depth and breadth enable clients to move beyond fragmented, activity-based metrics and instead focus on what truly matters – meaningful shifts in HCP understanding, engagement, and behavior. 

Discover how Intelligent Congress can help you create more strategic, measurable, and impactful HCP engagement. Visit our congress page or connect with the Inizio team at booth 21157 during the ASCO® Annual Meeting 2026 to see Intelligent Congress in action. 

Read full article here.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Nutraceuticals: Rich in Potential

Published in eyeforpharma October 2016 by Marc Yates

Case Study: Qualitative research with payers in low and middle income countries

Our client wanted to understand in detail the usage decision drivers, triggers and processes for a high-cost innovative Acute Heart Failure (AHF) drug used in the acute emergency setting in...

Case study: Leveraging Market Research Data to Inform Healthcare Providers and the Community

Our client wanted to understand why uptake of HPV vaccination in the Asia-Pacific region was limited.  In order to help increase uptake, they wanted to publish the market research findings...

Towards a culture of evaluation and evidence-based decision making in global health

Reflections on THET Conference 2016: Evidence, Effectiveness & Impact

Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016

Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe. Living with UC is a quantitative study conducted online amongst 325 patients, including...

The Internet of Things

Evolution from man to machine

Therapy Watch expands its oncology portfolio

This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). Therapy Watch SCCHN is part of a wider portfolio...

Time for a new language for asthma?

Despite the global advances made in the treatment for asthma, many studies have shown that asthma remains uncontrolled for a large proportion of patients, when assessed according to international guidelines....

Evaluating the impact of your medical congress presence…more cost effectively

Organising a company’s presence, not just logistically, but in terms of delivering key information, data and messages, is a massive part of some people’s workload at this time of year....